Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) ...

Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...

NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...

In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity.

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care ...

China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

Novo Nordisk (NVO) stock rises after full results from an early-stage trial of weight-loss pill amycretin. Read more here.

There are currently no pharmaceutical treatments approved for general obesity in under-12s — as opposed to that found with some rare genetic disorders — said Claudia Fox, a professor from University ...